VRB-103 / Sciwind Biosci, Verdiva Bio - LARVOL DELTA

Efficacy of a novel oral amylin analogue and the development of an oral GLP-1/amylin co-formulated tablet to produce high in vivo plasma exposures (EASD 2025) - "In a preclinical model, the combination of the amylin analog VRB-103 and GLP-1 analog VRB-101 demonstrated a synergistic effect on body weight reduction. Both VRB-103 and VRB-101 achieved high plasma exposures in cynomolgus monkeys when dosed orally from a single co-formulated tablet containing VRB-103, VRB-101, and the oral permeation enhancer T2026, supporting continued development of the oral GLP-1/amylin combination for the treatment of obesity and type 2 diabetes."

Preclinical • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Efficacy of a Novel Oral Amylin Analog and the Development of an Oral GLP-1/Amylin Coformulated Tablet to Produce High In Vivo Plasma Exposures (ADA 2025) - "In a preclinical model, the combination of the amylin analog VRB103 and VRB101 demonstrated a synergistic effect on body weight reduction. Both VRB103 and VRB101 achieved high plasma exposures in cynomolgus monkeys when dosed orally from a single co-formulated tablet containing VRB103, VRB101, and T2026, supporting continued development of the oral GLP-1/amylin combination for the treatment of obesity and type 2 diabetes."

Preclinical • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Sciwind Biosciences Announces Global Licensing and Collaboration Agreement for Metabolic Disease Portfolio (PRNewswire) - "Hangzhou Sciwind Biosciences...today announced a licensing and collaboration agreement for the global development and commercialization of a portfolio of metabolic diseases therapies in territories outside of Greater China and South Korea, with Verdiva Bio Limited ('Verdiva')...The partnered portfolio under this collaboration includes: Oral Ecnoglutide (Ecnoglutide Oral, XW004): A phase 2-ready, potential first-in-class, once-weekly oral GLP-1 receptor agonist. Oral Amylin Receptor Agonist (Amylin RA): A potential first-in-class, once-weekly long-acting, oral amylin receptor agonist in IND-enabling studies. Subcutaneous injectable Amylin Receptor Agonist (Amylin RA): A potential best-in-class, long-acting, amylin receptor agonist in IND-enabling studies....Under the agreement, Sciwind receives an upfront consideration totaling approximately $70 million, and is eligible to receive more than $2.4 billion in milestone payments for development,..."

Licensing / partnership • Metabolic Disorders • Obesity